- Home
- ASA vs NBTX Comparison
ASA vs NBTX Comparison
Compare ASA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASA | NBTX |
|---|---|---|
| Founded | 1958 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.9M | 1.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ASA | NBTX |
|---|---|---|
| Price | $61.98 | $20.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 106.0K | 37.7K |
| Earning Date | 01-27-2026 | 09-30-2025 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 335.96 | N/A |
| EPS | ★ 19.90 | N/A |
| Revenue | $3,982,215.00 | ★ $11,930,711.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $145.24 |
| P/E Ratio | $3.11 | ★ N/A |
| Revenue Growth | ★ 99.75 | N/A |
| 52 Week Low | $21.17 | $2.82 |
| 52 Week High | $63.02 | $30.35 |
Technical Indicators
Market Signals| Indicator | ASA | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.99 | 43.48 |
| Support Level | $58.72 | $19.75 |
| Resistance Level | $62.82 | $21.68 |
| Average True Range (ATR) | 2.16 | 1.07 |
| MACD | -0.23 | -0.33 |
| Stochastic Oscillator | 80.76 | 11.27 |
Price Performance
Historical ComparisonAbout ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.